Trial Profile
A Phase II Study of TRC105 in Adults With Advanced/Mestastic Urothelial Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2017
Price :
$35
*
At a glance
- Drugs Carotuximab (Primary)
- Indications Bladder cancer; Pelvic cancer; Renal cancer; Urethral cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Feb 2012 Actual patients number is 13 as reported by ClinicalTrials.gov.
- 02 Dec 2011 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.